两性霉素B脂质体治疗肺真菌病的疗效及安全性  

Efficacy and safety of liposome amphotericin B for the treatment of pneumonomycosis

作　　者：王春晖[1] 叶晓芬[1] 吕迁洲[1] 

机构地区：[1]复旦大学附属中山医院药剂科,上海200032

出　　处：《上海医药》2016年第1期39-42,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：上海市科委产学研医项目<两性霉素B脂质体和盐酸头孢替安临床合理用药及安全性研究>(项目编号:12DZ1930403)

摘　　要：目的:回顾性调查与分析两性霉素B脂质体治疗真菌感染的疗效及安全性。方法:收集2013年11月-2015年6月我院使用两性霉素B脂质体治疗肺真菌病的病例,以痊愈、显效、进步、无效4种评价标准对其疗效进行评价,并对不良反应进行分析。结果:12例患者中痊愈1例,显效7例,进步1例,无效3例,有效率为66.67%。12例患者均出现不同程度的药物不良反应,仅1例患者因严重肾功能损害停药。结论:两性霉素B脂质体作为肺真菌病的一线治疗药物,疗效可靠,不良反应可控。Objective：To retrospectively investigate and analyze the efficacy and safety of liposome amphotericin B for the treatment of pneumonomycosis.Methods：Pneumonomycosis cases received liposome amphotericin B treatment were collected from November 2013 to June 2015 in our hospital and their outcomes were assessed in four evaluation criteria such as cured,effective,improved or unresponsive,and adverse drug reactions（ADR） were analyzed as well.Results：One patient was cured,seven patients were effective,while one was improved and three were unresponsive to the therapy in12 patients and the effective rate accounted for 66.67%.All cases experienced different levels of ADR,however,only one case had to stop treating because of severe renal dysfunction.Conclusions：The efficacy of liposome amphotericin B as the first-line therapeutic drug for pneumonomycosis is reliable and its ADRs are controllable.

关 键 词：两性霉素B脂质体 疗效 安全性 药物不良反应 

分 类 号：R519[医药卫生—内科学]